Cooper Cos Inc Dossier
Qualitative Analysis
Business overview
The Cooper Companies, Inc. (CooperCompanies) is a leading global medical device company focused on improving vision, fertility, and women's health. Operating through two primary business segments, CooperVision and CooperSurgical, the company sells products in over 130 countries. CooperVision is a global manufacturer of contact lenses, offering a broad portfolio of single-use, two-week, and monthly lenses designed to address vision challenges such as astigmatism, presbyopia, and myopia. CooperSurgical focuses on family and women's healthcare, providing fertility consumables, genomic services, medical devices, and contraception solutions.
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
The board and management, assisted by advisers, are reviewing the company's businesses, corporate structure, strategy, operations and capital-allocation priorities, including potential partnerships, joint ventures, divestitures, mergers and business combinations.
Expected impact: The stated objective is to simplify the business, improve performance in core markets and identify opportunities to unlock long-term shareholder value.
CooperVision is expanding MyDay MiSight 1 day and MiSight 1 day across additional markets. MyDay MiSight combines MiSight ActivControl technology with the silicone-hydrogel material used in MyDay lenses.
Expected impact: The initiative expands access to evidence-based pediatric myopia-control products and strengthens CooperVision's premium daily-disposable and myopia-management portfolio.
Management is pursuing organizational alignment, cost-structure optimization and operating discipline while directing cash toward growth investments, share repurchases and debt reduction.
Expected impact: Management expects efficiency gains to support profitable growth and margin performance, while more than $2.2 billion of targeted three-year free cash flow would provide capital-allocation flexibility.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
The acquisition added single-use cordless illuminated surgical retractors and suction devices, broadening CooperSurgical's surgical portfolio and complementing its INSORB, Lone Star and Doppler Blood Flow Monitor products.
Financial impact: At announcement, the acquired products had approximately $14.5 million of trailing-twelve-month revenue; the transaction was expected to be neutral to fiscal 2024 non-GAAP EPS and accretive thereafter.
The acquired minimally invasive products, including the Bakri Postpartum Balloon, cervical-ripening balloon, Doppler Blood Flow Monitor portfolio and selected surgical products, were described as highly synergistic with CooperSurgical's women's-health medical-device portfolio.
Financial impact: At closing, the assets had approximately $56 million of trailing-twelve-month revenue. Management expected the acquisition to add approximately $0.20 to fiscal 2024 non-GAAP EPS, excluding one-time charges and deal-related amortization.